Navigation Links
Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
Date:5/7/2008

Study to Evaluate Preferred Induction Dosing Regimen

SEATTLE, May 7 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that its partner, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has commenced patient dosing in the next Phase 2b clinical trial of TRU-015 in patients with rheumatoid arthritis (RA). In collaboration with Trubion, Wyeth Pharmaceuticals is developing TRU-015, SBI-087 and other CD20-directed products.

The randomized, parallel, double-blind, placebo-controlled, dose regimen-finding study will evaluate the safety and efficacy of two dosing regimens administered to approximately 216 patients with active, seropositive RA on a background of methotrexate. The primary outcome measurement for the TRU-015 Phase 2b study will be the American College of Rheumatology (ACR) 50 response measured at 24 weeks. Secondary outcome measurements will be ACR 20 and 70 and DAS-28 responses.

"Data reported previously demonstrates TRU-015's ability to significantly improve RA signs and symptoms, and maintain response rates with repeat administration of single doses given every six months," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "This study is designed to help us identify an induction, or initial, dosing regimen and allow us to further establish the most effective treatment regimen for TRU-015. We believe this study has been designed in a way that could support a registration package, and we look forward to the results of
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Intelomed is pleased to announce that ... as the Vice President of Clinical Affairs. With over ... device industry, Kay,s experience in taking medical technology and ... to global expansion, is a valuable addition to the ... on our team, and I am confident her focused ...
(Date:8/26/2014)... Research and Markets has announced ... Report 2014 " report to their offering. ... is a professional and in-depth study on the current ... The report provides a basic overview of the industry ... glucose meter market analysis is provided for both the ...
(Date:8/26/2014)... DUBLIN , Aug. 26, 2014 ... "Global Intranasal Drug Delivery Market 2014-2018" report ... is a medical device used for the administration of ... nose and paranasal sinus such as allergic and non-allergic ... an ideal administrative route for needle-free vaccination and systematic ...
Breaking Medicine Technology:Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2Global Glucose Meter Industry Report 2014 2Global Glucose Meter Industry Report 2014 3Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
(Date:8/27/2014)... 2014 Aspirus Wausau Hospital today announced ... with Buzz™ Digital O.R. at Aspirus Wausau Hospital, in ... new operating rooms will be Buzz, a centralized surgical ... system supports planning, navigation, imaging and communications connectivity. ... intuitive software and hardware all controlled from the full ...
(Date:8/27/2014)... 26, 2014 (HealthDay News) -- Health care workers in ... to keep them safe from being infected with blood-borne ... shows. While the study was conducted before the ... its findings are confirmed in statistics released Monday by ... agency reported that an "unprecedented" number of health care ...
(Date:8/27/2014)... patients are 70 per cent more likely to continue ... they have a prescription in hand when discharged ... the Institute for Clinical Evaluative Sciences (ICES). , Using ... Ontarians were taking their medications one week, one year ... reveal the importance of simple interventions, such as giving ...
(Date:8/27/2014)... Hills, CA (PRWEB) August 27, 2014 Bedros ... camp franchise in the world, the leading fitness boot ... Spike TV’s Gym Rescue reality series. One thing he knows ... brand as a subject matter expert in the fitness business. ... to YouTube, he lays out a step-by-step instructional guide on ...
(Date:8/27/2014)... Phoenix, AZ (PRWEB) August 27, 2014 ... that serves the greater Phoenix metropolitan area and all ... client more than $160,000 on a $2 million settlement. ... tangible savings to those who have been injured through ... can be complex and time-consuming, however Hastings and Hastings ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 2Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 3Health News:A prescription for better stroke care 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $166,700 On A Settlement Of $2,000,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $166,700 On A Settlement Of $2,000,000 3
... has been released by Australian obesity experts that show gastric ... conference on obesity in Sydney there were three studies which ... in mortality rates in obese people who had the surgery. ... upper part of the stomach for the procedure to restrict ...
... a 4- to 5-point IQ advantage over women by adulthood. ... to 18-year-//olds on the Scholastic Assessment Test (SAT). ... because girls mature faster than boys. This is the reason ... ,145 items from the SAT were examined by a study ...
... of the opinion that eating nuts about twice a week might ... that was presented at the World Congress of Cardiology stated that ... would be around a small plate full might reduce the risk ... survey confirmed that eating a small quantity of the same kinds ...
... hang heavy with heart problems, going back at least two ... she hit age 50,// Catherine got nervous. ,A ... and perhaps those of others in her family tree. She ... causes her heart muscle to grow too thick. The extra ...
... Industry in China has placed on record the successful initial ... vaccine is said to operate in low doses, nearly one-third ... undertaken till date. The smaller doses are proven to be ... observed that just two 10-microgram doses of the Sinovac vaccine, ...
... Scottish Executive have announced their plans to offer dental students ... them in the NHS.// ,It has been explained ... given ?4,000 a year in return for a commitment of ... ,Lewis Macdonald, the deputy health minister, had announced the launch ...
Cached Medicine News:Health News:Greater g factor in men responsible for sex differences in general mental ability 2Health News:Greater g factor in men responsible for sex differences in general mental ability 3Health News:Fight Back Against Inherited Sudden-Death Heart Condition 2Health News:Fight Back Against Inherited Sudden-Death Heart Condition 3Health News:Fight Back Against Inherited Sudden-Death Heart Condition 4
... with ease of use make the OM-5 ... Ideal for office or hospital-based urodynamics, the ... cystometry, leak point pressure, or urethral pressure ... make the OM-5 flexible enough to meet ...
Windows-Based Urodynamics for Fast and Straightforward. Testing For Clinics Where Logic and Efficiency are at a Premium...
... The Corkscrew FT II (fully threaded) ... anchor designed to be inserted flush with ... strength and anchor stability. The full thread ... suture anchors with protruding eyelets. Especially advantageous ...
... (fully threaded) is a 5.5 mm diameter ... flush with the cortical bone surface to ... fully threaded design substantially improves pull-out strength ... The fully threaded design prevents anchor pull-back ...
Medicine Products: